Now Approved for Lupus Nephritis

BENLYSTA is Designed

for Lupus

BENLYSTA is indicated for patients aged ≥5 with active, autoantibody-positive systemic lupus erythematosus (SLE) receiving standard therapy and patients aged ≥18 with active lupus nephritis receiving standard therapy. The subcutaneous (SC) formulation is approved for patients aged ≥18. BENLYSTA is not recommended in patients with severe active central nervous system lupus or in combination with other biologics.

SEE THE SLE TRIAL RESULTS:1-3

Icon: Disease Activity

Disease activity

Primary endpoint

Icon: Severe Flare

Risk of severe flare

Secondary endpoint

Icon: Steroid Dose

Steroid dose

Secondary endpoint

You can now use BENLYSTA for your patients with lupus nephritis

Based on the results of BLISS-LN, BENLYSTA can now be used in patients with lupus nephritis.

 

VIEW THE LN TRIAL DATA

Icon: BENLYSTA Efficacy

Established Efficacy in SLE

BENLYSTA has demonstrated efficacy across a variety of patient types.

Learn More

Icon: Real World Experience

Real-World Evidence

Find out about BENLYSTA and organ damage accrual in the real-world setting.

Learn More

Icon: BENLYSTA Dosing Options

Dosing Flexibility

BENLYSTA is available in multiple formulations for adult patients. Talk to your patients about which formulation is right for them.

Learn More

Icon: Silhouette

Safety

BENLYSTA has a safety profile observed in 8 clinical trials.

Learn More

Who is your Benlysta patient?

SLE

42 years old

Diagnosed with SLE 6 years ago

Meet Lindsay

LN

34 years old

Diagnosed with LN 4 years ago

Meet Ashley

Pediatric SLE

12 years old

Diagnosed with SLE 3 years ago

Meet Sophia

BENLYSTA is now available for more of your patients